Severe maculopapular eruption due to pseudoephedrine in a combination drug, with cross‐reactivity to phenylephrine

2021 ◽  
Author(s):  
Alejandro Raúl Gratacós Gómez ◽  
Oscar Marcelo González Jimenez ◽  
Alberto Palacios Cañas ◽  
Lucia Moreno Lozano ◽  
Miguel Juan Cencerrado ◽  
...  
Keyword(s):  
Cross Reactivity ◽  
Combination Drug ◽  
Maculopapular Eruption

Hypersensitivity reactions to proton-pump inhibitors: Clinical presentation, diagnosis, and management

2020 ◽  
Vol 41 (2) ◽  
pp. e37-e44 ◽  
Author(s):  
Seçil Kepil Özdemir ◽  
Sevim Bavbek
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Clinical Presentation ◽  
Current Knowledge ◽  
Cross Reactivity ◽  
Delayed Hypersensitivity ◽  
Stevens Johnson Syndrome ◽  
Hypersensitivity Reactions ◽  
Fixed Drug Eruption ◽  
Maculopapular Eruption

Background: Proton-pump inhibitors (PPI) are one of the most commonly prescribed drugs, and they are generally well tolerated. However, several immediate and delayed hypersensitivity reactions due to PPIs have been reported. Objective: To review the clinical characteristics and management of immune-mediated immediate and delayed hypersensitivity reactions to PPIs. Methods: We performed a search of a medical literature data base from January 1980 to October 2019 by using keywords that included “proton-pump inhibitors” and “hypersensitivity.” Results: Anaphylaxis is the most-common clinical presentation in patients with immediate hypersensitivity reactions to PPIs, followed by urticaria and/or angioedema. Occupational contact dermatitis, maculopapular eruption, fixed drug eruption, symmetrical drug-related intertriginous and flexural exanthema, and severe cutaneous adverse reactions, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms, and acute generalized exanthematous pustulosis have also been reported with PPIs. Conclusion: The current knowledge and severity of the reported reactions indicated the importance of consideration of a causal relationship between hypersensitivity reactions and PPIs, and awareness of the existence of cross-reactivity among PPIs.

scholarly journals Maculopapular delayed exanthema due to ranitidine

2020 ◽  
Vol 4 (1) ◽  
pp. 014-016
Author(s):  
Alfonso Pilar Hernández ◽  
Mahave Idoia González ◽  
Oribe Irene Vidal ◽  
del Pozo Gil Mª Dolores ◽  
Díaz Mónica Venturini ◽  
...  
Keyword(s):  
Patch Testing ◽  
Oral Treatment ◽  
Cross Reactivity ◽  
Receptor Antagonists ◽  
H2 Receptor Antagonists ◽  
Delayed Reaction ◽  
H2 Receptor ◽  
Systemic Involvement ◽  
Maculopapular Eruption ◽  
Special Cases

Ranitidine is a widely used drug in Europe and its intake is usually well tolerated. Hypersensitivity reactions due to ranitidine are uncommon. The immediate mild reactions type are the most prevalent. In some special cases a delayed type reaction such as contact dermatitis or severe reactions with systemic involvement have been reported. In the present paper, a case report of a 78-year old patient who experienced a maculopapular eruption after 7 days of oral treatment with ranitidine is described. Patch tests were performed twice with ranitidine with positive results confirming the diagnosis. In order to discard a double sensitization and a possible cross-reactivity phenomenon, patch test was performed once with famotidine, with a negative result. This is the first maculopapular exanthema reported as type IV hypersensitivity reaction to ranitidine confirmed by patch testing. Moreover, there are only two reported cases showing a double sensitization to ranitidine and to other H2-receptor antagonists by patch testing after a delayed reaction due to ranitidine, the other being H2-receptor antagonists involving cimetidine and nizatidine, not famotidine.

scholarly journals A case of delayed maculopapular eruption to ibuprofen and acute urticaria to acetaminophen

2021 ◽  
Vol 9 ◽  
pp. 2050313X2110564
Author(s):  
Jason Wong ◽  
Ashley Sandoval ◽  
Tiffany Jean ◽  
Asal Gharib Naderi
Keyword(s):  
Immunoglobulin E ◽  
Maculopapular Rash ◽  
Initial Therapy ◽  
Cross Reactivity ◽  
Delayed Reaction ◽  
Acute Urticaria ◽  
Maculopapular Eruption ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Delayed Hypersensitivity Reaction

We present the unique case of a 33-year-old male referred to our clinic in search of analgesic options who was found to have a delayed hypersensitivity reaction to ibuprofen manifesting as a maculopapular rash and acute urticaria to acetaminophen. Non-steroidal anti-inflammatory drugs are associated with predictable reactions as well as immunoglobulin E-mediated reactions or T-cell mediated reactions. This case highlights the importance of knowledge of the different types of reactions to non-steroidal anti-inflammatory agents as well as the risk of cross reactivity. Delayed reaction to a single non-steroidal agent is rare; urticaria to acetaminophen is very rare. This is the first report we have found in the literature where one individual has a delayed reaction manifesting as rash to ibuprofen as well as urticaria to acetaminophen. We challenged our patient to aspirin which helped identify that his delayed reaction was only to ibuprofen and urticaria only to acetaminophen. The case also highlights the importance of an oral provocation challenge when no contraindications exist which helped us find that he could take celecoxib and avoid narcotics as initial therapy.

Maculopapular eruption in hypoparathyroidism

1976 ◽  
Vol 112 (7) ◽  
pp. 991-992 ◽  
Author(s):  
M. Waisman
Keyword(s):  
Maculopapular Eruption

Low-Dose Combination Drug Reduced Diabetes Risk

2010 ◽  
Vol 43 (12) ◽  
pp. 39
Author(s):  
HEIDI SPLETE
Keyword(s):  
Low Dose ◽  
Diabetes Risk ◽  
Combination Drug ◽  
Dose Combination

Concomitant Clinical Sensitivity (CCS) and Cross-Reactivity

2003 ◽  
Vol 15 (01) ◽  
pp. 018-029 ◽  
Author(s):  
Harris Steinman ◽  
Steve Lee
Keyword(s):  
Cross Reactivity ◽  
Clinical Sensitivity

Human Prothrombin Activation: Determination of Plasma and Serum Levels of Prothrombin Fragment 3 by Radioimmunoassay

1979 ◽  
Author(s):  
Daniel Walz ◽  
Thomas Brown
Keyword(s):  
Blood Clotting ◽  
Factor Xa ◽  
Heart Association ◽  
Serum Levels ◽  
Cross Reactivity ◽  
Assay Procedure ◽  
A Chain ◽  
Prothrombin Activation ◽  
Theoretical Amount

Human prothrombin activation is unique in that, in addition to the release of fragment 1.2 (FI.2) from the NH-terminus of prothrombin by factor Xa during the generation of thrombin, an additional 13 residue polypeptide, fragment 3 (F3), is autocatalytically removed from the amino-terminus of the thrombin A chain. We have developed a rapid radioimmunoassay for human F3 which incorporates short incubation times and the use of a preprecipitated second antibody; the assay can be performed in three hours. Specificity studies in buffer systems show prothrombin and prethrombin 1 cross-reacting at a level of 0.001; purified thrombin does not cross-react. In the presence of 5% BSA, prothrombin displays considerably less cross-reactivity. No immunoreactive material to F3 antibodies could be detected in 400 μL of plasma. Serum, obtained from whole blood clotting, contained measurable quantities of F3 (40-100 ng/mL). This amount in serum represents only 5-10% of the theoretical amount available should all of the fragment be hydrolytically cleaved during the conversion of prothrombin to thrombin. This assay procedure is currently being utilized to monitor the activation of purified human prothrombin in the absence and presence of selected plasma inhibitors. (Supported in part by NIH 05384-17 and the Michigan Heart Association).

Serological cross-reactivity between Sarcocystis and Toxoplasma in pigs

1987 ◽  
Vol 25 (2) ◽  
pp. 188 ◽  
Author(s):  
Moo Hong Moon
Keyword(s):  
Cross Reactivity

Determination of the Effect of a Teneligliptin-Canagliflozin Combination Drug Using Free Style Libre Pro

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 2304-PUB
Author(s):  
TAKAHIRO TOSAKI ◽  
HIDEKI KAMIYA ◽  
SHIORI SATO ◽  
AYAE KUDARA ◽  
AKEMI INAGAKI ◽  
...  
Keyword(s):  
Combination Drug

Cross-reactivity of organs in allograft rejection. Comparison of effect of thyroid allografts on established islet allografts

Diabetes ◽  
1987 ◽  
Vol 36 (11) ◽  
pp. 1268-1270
Author(s):  
K. Kover ◽  
O. Hegre ◽  
H. Popiela ◽  
T. Biggs ◽  
W. V. Moore
Keyword(s):  
Allograft Rejection ◽  
Cross Reactivity ◽  
Islet Allografts
Sign in / Sign up

Export Citation Format

Share Document